Abstract
3', 4'-Dideoxykanamycin B (DKB) is a new aminoglycoside antibiotic derived from kanamycin B by UMEZAWA, et al. This agent has a remarkable effectivenesst o kanamycin-resistantb acteria and Pseudomonas aeruginosa.
Studies on acute toxicity of DKB were carried out by intravenous, intramuscular, intraperitoneal, subcutaneous and oral administration to ICR strain mice and Wistar strain rats.
The LD50 values for male and female mice were 72.3 and 62.6 mg/kg (as base activity) i. v.; 604.7 and 430.9 mg/kg i. p.; 430.9 and 396.2 mg/kg i. m., and 528.2 and 521.3 mg/kg s.c., respectively. For mice administered with DKB orally, LD50 was over 6,950 mg/kg in both sexes. Those for male and female rats were 177.2 and 140.4 mg/kg i. v.; 799.3 and 1014.7 mg/kg i. p.; 559.5 and 576.9 mg/kg i. m., and 1,668.0 and 1,376.1 mg/kg s. c., respectively. Oral LD50 for rats was over 6,950 mg/kg, and there was no sex difference of the toxicity as well as in mice.
Slight degenerations were histopathologically observed in the kidney but not in the other organs of animals in each experimental group. These results were favourable in comparison with those of gentamicin used as a control agent.
